Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Åsa Lindberg, III, Christian Winther Eskelund, Alexandra Albertsson-Lindblad, MD PhD, Arne Kolstad, MD PhD, Anna Laurell, MD PhD, Riikka Räty, MD PhD, Kirsten Grønbæk, Prof,MDDMSc, Christian H. Geisler, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133370

Published: 2020

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, MD PhD, Martin Hutchings, MD PhD, Riikka Räty, MD PhD, Karin Fahl Wader, MD PhD, Anna Laurell, MD PhD, Jacob H. Christensen, MD, Hanne Kuitunen, MD, Christian Winther Eskelund, MD PhD, Kirsten Groenbaek, MD DMSc, Carsten Utoft Niemann, MD PhD, Christian H. Geisler, MD PhD, Arne Kolstad, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-133298

Published: 2020

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Hanne Kuitunen, Helle Toldbod, Lone Bredo Pedersen, Christian Winther Eskelund, Kirsten Grønbæk, Carsten Utoft Niemann, Christian H Geisler, Arne Kolstad

Blood (2016) 128 (22): 148.

https://doi.org/10.1182/blood.V128.22.148.148

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman

Blood (2016) 128 (14): 1814–1820.

https://doi.org/10.1182/blood-2016-03-704023

Published: 2016

Includes: Supplemental data

Journal Articles

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Blood (2015) 125 (17): 2669–2677.

https://doi.org/10.1182/blood-2014-06-584193

Published: 2015

Includes: Supplemental data

Journal Articles

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Simon Husby, MD, Lone Bredo Pedersen, Ulrik Ralfkiær, PhD-student, Christian Garde, Sara Ek, Arne Kolstad, MD PhD, Mats Jerkeman, MD PhD, Anna Laurell, Riikka Räty, Anja Pedersen, Christer Sundström, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, MD PhD, Erik Clasen-Linde, MD, Christopher Workman, PhD, Christian H Geisler, Kirsten Grønbæk, MD DMSc

Blood (2014) 124 (21): 2994.

https://doi.org/10.1182/blood.V124.21.2994.2994

Published: 2014

Journal Articles

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Blood (2014) 123 (19): 2953–2959.

https://doi.org/10.1182/blood-2013-12-541953

Published: 2014

Journal Articles

Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials

Blood (2013) 122 (21): 3367.

https://doi.org/10.1182/blood.V122.21.3367.3367

Published: 2013

Journal Articles

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

Lena Nordström, Venera Kuci, Sandra Sernbo, Kirsten Groenbaek, MD, DMSc, Arne Kolstad, Riika Räty, Marja-Liisa Karjalainen, Christian Geisler, Elisabeth Ralfkiaer, MD, DMSc, Christer Sundström, Anna Laurell, Jan Delabie, Mats Ehinger, Mats Jerkeman, Sara Ek

Blood (2013) 122 (21): 4272.

https://doi.org/10.1182/blood.V122.21.4272.4272

Published: 2013

Journal Articles

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial

Mats Jerkeman, Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Christian Geisler

Blood (2013) 122 (21): 4377.

https://doi.org/10.1182/blood.V122.21.4377.4377

Published: 2013

Journal Articles

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Blood (2012) 120 (21): 747.

https://doi.org/10.1182/blood.V120.21.747.747

Published: 2012

Journal Articles

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial

Mats Jerkeman, MD PhD, Arne Kolstad, MD, PhD, Anna Laurell, Riikka Räty, Kirsten Grønbæk, MD, DMSc, Lone Bredo Pedersen, Christian H. Geisler, PhD, MD

Blood (2011) 118 (21): 2700.

https://doi.org/10.1182/blood.V118.21.2700.2700

Published: 2011

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Blood (2010) 115 (8): 1530–1533.

https://doi.org/10.1182/blood-2009-08-236570

Published: 2010

Includes: Supplemental data

Journal Articles

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Blood (2009) 114 (22): 932.

https://doi.org/10.1182/blood.V114.22.932.932

Published: 2009

Journal Articles

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood (2008) 112 (7): 2687–2693.

https://doi.org/10.1182/blood-2008-03-147025

Published: 2008

Journal Articles

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Niels S. Andersen, MD, Lone B. Pedersen, Anna Laurell, MD, Erkki Elonen, MD, Arne Kolstad, MD, Christian H. Geisler, MD

Blood (2007) 110 (11): 1281.

https://doi.org/10.1182/blood.V110.11.1281.1281

Published: 2007

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in V H 3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

Blood (2006) 107 (7): 2889–2894.

https://doi.org/10.1182/blood-2005-06-2227

Published: 2006

Includes: Supplemental data

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, Ph.D, Arne Kolstad, MD, Ph.D, Anna Laurell, MD, Ph.D, Lone B. Pedersen, B of Sc, Niels S. Andersen, MD, Ph.D, Mats Jerkeman, MD, Ph.D, Marie Nordstrom, MD, Ph.D, Grethe F. Lauritzen, MD, Ph.D, Elisabeth Ralfkiaer, MD, Ph.D, Maans Akerman, MD, Ph.D, Christer Sundstrom, MD, Ph.D, Ruth Langholm, MD, Ph.D, Marja-Liisa Karjalainen-Lindsberg, MD, Ph.D, Outti Kuittinen, MD, Ph.D, Mikael Eriksson, MD, Ph.D, Nordic Lymphoma Group

Blood (2005) 106 (11): 2429.

https://doi.org/10.1182/blood.V106.11.2429.2429

Published: 2005

NARROW

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Successful Preemptive Treatment of Molecular Relapse after Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in V H 3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only